A Study of SGN-B6A in Advanced Solid Tumors : A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.The study will have four parts.Part A of the study will find out how much sigvotatug vedotin should be given to participants.Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.In Parts C and D, participants will receive sigvotatug vedotin with either:Pembrolizumab or,Pembrolizumab and carboplatin, orPembrolizumab and cisplatin..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 16. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 15, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 |
|---|
| Study ID: |
NCT04389632 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003392783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003392783 | ||
| 003 | DE-627 | ||
| 005 | 20240424010540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003392783 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04389632 | ||
| 035 | |a (UBBS_Klinische_Studien)SGNB6A-001 | ||
| 035 | |a (UBBS_Klinische_Studien)2023-508469-34 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study of SGN-B6A in Advanced Solid Tumors |b A Phase 1 Study of SGN-B6A in Advanced Solid Tumors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 15, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 | ||
| 520 | |a This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.The study will have four parts.Part A of the study will find out how much sigvotatug vedotin should be given to participants.Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.In Parts C and D, participants will receive sigvotatug vedotin with either:Pembrolizumab or,Pembrolizumab and carboplatin, orPembrolizumab and cisplatin. | ||
| 650 | 2 | |a Carcinoma | |
| 650 | 2 | |a Neoplasms | |
| 650 | 2 | |a Carcinoma, Squamous Cell | |
| 650 | 2 | |a Adenocarcinoma | |
| 650 | 2 | |a Breast Neoplasms | |
| 650 | 2 | |a Esophageal Squamous Cell Carcinoma | |
| 650 | 2 | |a Carcinoma, Non-Small-Cell Lung | |
| 650 | 2 | |a Neoplasms, Squamous Cell | |
| 650 | 2 | |a Ovarian Neoplasms | |
| 650 | 2 | |a Stomach Neoplasms | |
| 650 | 2 | |a Squamous Cell Carcinoma of Head and Neck | |
| 650 | 2 | |a Uterine Cervical Neoplasms | |
| 650 | 2 | |a Urinary Bladder Neoplasms | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a Phase: Phase 1 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 16. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04389632 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 | ||